FIG. 9.
Overexpression of Bcl-2 or Bcl-XL blocks the JNK pathway. (A) JT/Neo, JT/Bcl-2, and JT/Bcl-XL cells were treated with 100 nM TG for 4 h. The Western blots (IB) were performed with antibody specific to phosphoactive JNK (top panel) and anti-JNK1 antibody (bottom panel). (B) Cells were treated as described in panel A. The Western blots were performed with antibody specific to phosphoactive ERK (top panel) and anti-ERK2 antibody (bottom panel). (C) Cells were treated as described in panel A. The Western blots were performed with antibody specific to phosphoactive p38 (top panel) and anti-p38 antibody (bottom panel). For a positive control, a group of cells was also exposed to UVC (20 J/m2).